NDLI: Clinical trials and drug cost savings for Italian health service

Content Provider	Springer Nature : BioMed Central
Author	D’Ambrosio, Francesca De Feo, Gianfranco Botti, Gerardo Capasso, Arturo Pignata, Sandro Maiolino, Piera Triassi, Maria Nardone, Antonio Perrone, Franco Piezzo, Michela Grimaldi, Antonio Maria Palazzo, Ida De Stasio, Immacolata D’Aniello, Roberta Morabito, Alessandro Pascarella, Giacomo
Abstract	Background The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials. Methods We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. Results From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5487 Euros saved per patients for a period of 4 weeks. Conclusions Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.
Related Links	https://bmchealthservres.biomedcentral.com/counter/pdf/10.1186/s12913-020-05928-6.pdf
Ending Page	7
Page Count	7
Starting Page	1
File Format	HTM / HTML
ISSN	14726963
DOI	10.1186/s12913-020-05928-6
Journal	BMC Health Services Research
Issue Number	1
Volume Number	20
Language	English
Publisher	BioMed Central
Publisher Date	2020-11-26
Access Restriction	Open
Subject Keyword	Public Health Health Administration Health Informatics Nursing Research Clinical trials Cost savings Treatment costs Investigational drug Per-patient cost Drugs expenditure Cost reduction
Content Type	Text
Resource Type	Article
Subject	Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The costs and potential savings of a novel telepaediatric service in Queensland

Does the Patient Clinical Complexity Level (PCCL) reflect nursing acuity?

Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy

Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services

Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda

An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population

Clinical trials from the patient perspective: survey in an online patient community

Community pharmacists’ support for nursing mothers in Serbia: potential cost savings due to breastfeeding continuation

Clinical trials and drug cost savings for Italian health service

Similar Documents

The costs and potential savings of a novel telepaediatric service in Queensland

Does the Patient Clinical Complexity Level (PCCL) reflect nursing acuity?

Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy

Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services

Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda

An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population

Clinical trials from the patient perspective: survey in an online patient community

Community pharmacists’ support for nursing mothers in Serbia: potential cost savings due to breastfeeding continuation

Clinical trials and drug cost savings for Italian health service